Introduction
Asthma is a common medical condition in adults, with a prevalence of 4.5% in Malaysia, based on the National Health and Morbidity Survey 2006. It is an inflammatory disease of the airway which is triggered by external stimuli in genetically-predisposed individuals, leading to mucus secretion, bronchoconstriction and airway narrowing.
The most common symptom is a chronic cough. Misdiagnoses or underdiagnoses cause persistent airway inflammation, airway remodeling, and subsequently, fixed airway obstruction. Therefore, it is important for healthcare professionals to diagnose and manage asthma confidently.
Risk Factors
Asthma is a multifactorial disease brought about by various familial and environmental influences, as seen in Table 1 
Diagnosis
The diagnosis of asthma is based on a combination of clinical features suggestive of reversible airway obstruction supported by investigations, as shown in Tables 2 and 3 . A response to treatment may support the diagnosis; however, a lack of response does not exclude asthma. 
General Principles of Management
The aims of management are to achieve good asthma symptom control and minimise future risk of exacerbations. The partnership between the patients/caregivers and healthcare providers is important in ensuring the success of the management. The patient's preferences for treatment, ability to use an inhaler correctly, side effects and cost of medications should be taken into consideration during the treatment process.
Asthma Self-Management
The patient's active participation is important in asthma management. All patients should be made aware of the components of asthma self-management, which include:
• self-monitoring of symptoms and/or PEF • a written asthma action plan (WAAP) for optimisation of asthma control through self-adjustment of medications
• a regular medical review by healthcare providers A home nebuliser should be avoided, as it leads to underestimation of the severity of an acute exacerbation of asthma.
Stable Asthma
Stable asthma is defined as the absence of symptoms, no limitations on activities and not requiring any relievers in the last four weeks.
a. Assessment of asthma control
Asthma control can be assessed by using Asthma Control Test (ACT) scores or asking recommended questions, as shown in Table  4 below.
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b. Assessment of the severity of future risks
Assessment of the risk factors for a poor asthma outcome is important in treatment adjustments and prediction of exacerbation. Refer to Table 5 for more details. • Local: high-dose or potent ICS, poor inhaler technique
c. Treatment
The goal of asthma treatment is to achieve and maintain symptom control. This is done using a stepwise approach, as shown in Figure 1 . Stepwise treatment ladder in stable asthma
• Reliever
Inhaled SABA are the reliever of choice in stable asthma. Oral SABA should be avoided in asthma due to their side effects.
A low dose of budesonide/formoterol or beclometasone/formoterol may be used as a single inhalant for maintenance and reliever therapy in moderate to severe asthma.
Inhaled long-acting β 2 -agonists without ICS should not be used in reliever monotherapy in stable asthma.
• 
Non-Pharmacological Treatment
Non-pharmacological treatments may improve symptom control and/or reduce future risk of asthma exacerbation. This includes smoking cessation, vaccination and weight loss management.
Acute Exacerbation of Asthma
Acute exacerbation of asthma is defined as a progressive or sudden onset of worsening symptoms. Status asthmaticus is a lifethreatening and medical emergency situation.
a. Assessment of severity and management
Rapid clinical assessment of severity (refer to Table 6 ) should be performed in all acute exacerbation of asthma. Treatment should be initiated immediately based on the severity of the asthma (refer to Algorithm 1). In acute exacerbation of asthma, inhaled β 2 -agonists are the first-line treatment.
• In mild to moderate exacerbations, a pressurised metered dose inhaler with a spacer is the preferred method of delivery.
• In severe and life-threatening exacerbations, continuous delivery of nebulised oxygen-driven β 2 -agonists should be used.
Systemic corticosteroids should be given to all patients with acute exacerbation of asthma. They should be continued for 5 to 7 days. Asthma patients prescribed OCS should continue their regular ICS.
b. Criteria for admission/discharge
All patients with severe, life-threatening asthma and those with PEF<75% personal best or predicted one hour after initial treatment should be admitted. The following factors may be considered for admission:
• persistent symptoms 
